DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s11864-000-0039-4, but it redirected us to https://link.springer.com/article/10.1007/s11864-000-0039-4. The analysis below is for the second page.

Title[redir]:
Gastrointestinal stromal tumors | Current Treatment Options in Oncology
Description:
The nonepithelial, nonlymphoid tumors of the gastrointestinal tract are heterogeneous in terms of clinical presentation, behavior, pathology, and genetic features. Concepts regarding these tumors have changed rapidly over the past decade as nomenclature has evolved. Many of these tumors have no muscle differentiation, and designations such as leiomyoma or leiomyosarcoma are inappropriate for many of these neoplasms. With an improved understanding of the biology of these tumors, gastrointestinal stromal tumor (GIST) is used as a specific term for tumors of the gastrointestinal tract that lack markers of myogenic differentiation, but stain positive for vimentin, and express CD34 and CD117, the product of the c-kit oncogene. Both benign and malignant types are recognized. In addition to myogenic tumors and GIST, gastrointestinal autonomic nerve tumors (GANT) are also recognized. Complete en bloc surgical resection, when possible, is the cornerstone of therapy. Metastasis tends to occur to the liver and within the peritoneal cavity, especially in patients whose tumors have ruptured spontaneously or been violated by the surgeon. Incomplete surgical resection and metastatic disease indicate a dismal prognosis in the majority of patients. Recurrent or metastatic disease is often resected, but this has an uncertain impact on outcome. Operation may palliate patients with intestinal obstruction or other symptoms. For patients with unresectable disease, the results with systemic chemotherapy have been dismal. Treatment with doxorubicin/ifosfamide combinations is of dubious value. Hepatic arterial embolization, with and without intra-arterial chemotherapy, results in regression of liver metastases in selected patients. Regression has also been seen using intrahepatic arterial infusion of doxorubicin without embolization. The impact of such treatment on outcome, however, is poorly studied. Aggressive surgical resection of peritoneal metastases with intraperitoneal chemotherapy has been advocated, but requires formal study in large trials.

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 9,135,289 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

The income method remains a mystery to us.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Doi.org might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

gastrointestinal, article, google, scholar, tumors, pubmed, cas, stromal, patients, cancer, sarcoma, surg, pathol, disease, treatment, oncology, casper, tumor, chemotherapy, sarcomas, privacy, cookies, content, data, tract, gist, surgical, metastatic, doxorubicin, study, access, ann, sarlomorikala, clin, oncol, publish, research, search, muscle, differentiation, ckit, resection, liver, recurrent, results, review, authors, miettinen, entity, prognostic,

Topics {✒️}

month download article/chapter gastrointestinal stromal tumours cancer soft tissue related subjects soft-tissue sarcoma gastric stromal sarcoma c-kit occur preferentially adjuvant intraperitoneal chemotherapy gastrointestinal stromal tumor gastrointestinal stromal tumor gastrointestinal smooth-muscle full article pdf incomplete surgical resection aggressive surgical resection gastrointestinal leiomyosarcoma metastatic gastrointestinal stromal tumors privacy choices/manage cookies smooth muscle tumors recurrent abdominopelvic sarcoma soft-tissue sarcomas intra-arterial chemotherapy bolus versus infusion c-kit oncogene protooncogene c-kit c-kit ligand intraperitoneal chemotherapy kit gene [letter] intrahepatic arterial infusion requires formal study dna copy number armed forces institute massachusetts general hospital extra-adrenal paraganglioma memorial sloan kettering primary gastrointestinal sarcomas durable tumor regression check access instant access recurrent abdominal sarcomas conditions privacy policy hepatic chemoembolization infusion european economic area comprehensive discussion phase iii comparison surgical resection accepting optional cookies article casper erlandson ra small bowel neoplasms weekly clinicopathological exercises

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Gastrointestinal stromal tumors
         description:The nonepithelial, nonlymphoid tumors of the gastrointestinal tract are heterogeneous in terms of clinical presentation, behavior, pathology, and genetic features. Concepts regarding these tumors have changed rapidly over the past decade as nomenclature has evolved. Many of these tumors have no muscle differentiation, and designations such as leiomyoma or leiomyosarcoma are inappropriate for many of these neoplasms. With an improved understanding of the biology of these tumors, gastrointestinal stromal tumor (GIST) is used as a specific term for tumors of the gastrointestinal tract that lack markers of myogenic differentiation, but stain positive for vimentin, and express CD34 and CD117, the product of the c-kit oncogene. Both benign and malignant types are recognized. In addition to myogenic tumors and GIST, gastrointestinal autonomic nerve tumors (GANT) are also recognized. Complete en bloc surgical resection, when possible, is the cornerstone of therapy. Metastasis tends to occur to the liver and within the peritoneal cavity, especially in patients whose tumors have ruptured spontaneously or been violated by the surgeon. Incomplete surgical resection and metastatic disease indicate a dismal prognosis in the majority of patients. Recurrent or metastatic disease is often resected, but this has an uncertain impact on outcome. Operation may palliate patients with intestinal obstruction or other symptoms. For patients with unresectable disease, the results with systemic chemotherapy have been dismal. Treatment with doxorubicin/ifosfamide combinations is of dubious value. Hepatic arterial embolization, with and without intra-arterial chemotherapy, results in regression of liver metastases in selected patients. Regression has also been seen using intrahepatic arterial infusion of doxorubicin without embolization. The impact of such treatment on outcome, however, is poorly studied. Aggressive surgical resection of peritoneal metastases with intraperitoneal chemotherapy has been advocated, but requires formal study in large trials.
         datePublished:
         dateModified:
         pageStart:267
         pageEnd:273
         sameAs:https://doi.org/10.1007/s11864-000-0039-4
         keywords:
            Sarcoma
            Gastrointestinal Stromal Tumor
            Leiomyosarcoma
            Intraperitoneal Chemotherapy
            Compute Tomogra
            Oncology
         image:
         isPartOf:
            name:Current Treatment Options in Oncology
            issn:
               1534-6277
               1527-2729
            volumeNumber:1
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Current Medicine Group
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ephraim S. Casper
               affiliation:
                     name:Memorial Sloan Kettering at Saint Clare’s
                     address:
                        name:Chief, Medical Oncology, Memorial Sloan Kettering at Saint Clare’s, Denville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Gastrointestinal stromal tumors
      description:The nonepithelial, nonlymphoid tumors of the gastrointestinal tract are heterogeneous in terms of clinical presentation, behavior, pathology, and genetic features. Concepts regarding these tumors have changed rapidly over the past decade as nomenclature has evolved. Many of these tumors have no muscle differentiation, and designations such as leiomyoma or leiomyosarcoma are inappropriate for many of these neoplasms. With an improved understanding of the biology of these tumors, gastrointestinal stromal tumor (GIST) is used as a specific term for tumors of the gastrointestinal tract that lack markers of myogenic differentiation, but stain positive for vimentin, and express CD34 and CD117, the product of the c-kit oncogene. Both benign and malignant types are recognized. In addition to myogenic tumors and GIST, gastrointestinal autonomic nerve tumors (GANT) are also recognized. Complete en bloc surgical resection, when possible, is the cornerstone of therapy. Metastasis tends to occur to the liver and within the peritoneal cavity, especially in patients whose tumors have ruptured spontaneously or been violated by the surgeon. Incomplete surgical resection and metastatic disease indicate a dismal prognosis in the majority of patients. Recurrent or metastatic disease is often resected, but this has an uncertain impact on outcome. Operation may palliate patients with intestinal obstruction or other symptoms. For patients with unresectable disease, the results with systemic chemotherapy have been dismal. Treatment with doxorubicin/ifosfamide combinations is of dubious value. Hepatic arterial embolization, with and without intra-arterial chemotherapy, results in regression of liver metastases in selected patients. Regression has also been seen using intrahepatic arterial infusion of doxorubicin without embolization. The impact of such treatment on outcome, however, is poorly studied. Aggressive surgical resection of peritoneal metastases with intraperitoneal chemotherapy has been advocated, but requires formal study in large trials.
      datePublished:
      dateModified:
      pageStart:267
      pageEnd:273
      sameAs:https://doi.org/10.1007/s11864-000-0039-4
      keywords:
         Sarcoma
         Gastrointestinal Stromal Tumor
         Leiomyosarcoma
         Intraperitoneal Chemotherapy
         Compute Tomogra
         Oncology
      image:
      isPartOf:
         name:Current Treatment Options in Oncology
         issn:
            1534-6277
            1527-2729
         volumeNumber:1
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Current Medicine Group
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ephraim S. Casper
            affiliation:
                  name:Memorial Sloan Kettering at Saint Clare’s
                  address:
                     name:Chief, Medical Oncology, Memorial Sloan Kettering at Saint Clare’s, Denville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Treatment Options in Oncology
      issn:
         1534-6277
         1527-2729
      volumeNumber:1
Organization:
      name:Current Medicine Group
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Memorial Sloan Kettering at Saint Clare’s
      address:
         name:Chief, Medical Oncology, Memorial Sloan Kettering at Saint Clare’s, Denville, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ephraim S. Casper
      affiliation:
            name:Memorial Sloan Kettering at Saint Clare’s
            address:
               name:Chief, Medical Oncology, Memorial Sloan Kettering at Saint Clare’s, Denville, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Chief, Medical Oncology, Memorial Sloan Kettering at Saint Clare’s, Denville, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(141)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.34s.